← ANALYST RATINGS · TIPRANKS
Orasure Technologies (OSUR): analyst forecast and price target
Analyst consensus
0 Buy0 Hold0 Sell
Ratings of 0 analysts in the last 3 months12-month forecast
Based on 0 price targets given in the last 3 months, the average target is —, the highest —, the lowest —. The average is — from the last price of $3.61.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Instruments and SuppliesxAI Grok-3 | TipRanks - xAI | $3.50 | Hold | −3.0% | Reiterated | 21.09.26on TipRanks Sep 20 23:06 | — | |
| AI DeepSeek Medical - Instruments and SuppliesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 | Hold | −3.0% | Reiterated | 21.09.26on TipRanks Sep 20 23:06 | — | |
| AI OpenAI Medical - Instruments and SuppliesOpenAI 5.2 | TipRanks - OpenAI | $3.50 | Hold | −3.0% | Reiterated | 21.09.26on TipRanks Sep 20 23:06 | — | |
| AI Anthropic Medical - Instruments and SuppliesAnthropic Opus-4.5 | TipRanks - Anthropic | $3.50 | Hold | −3.0% | Reiterated | 21.09.26on TipRanks Sep 20 23:06 | — | |
| AI Google Medical - Instruments and SuppliesGemini 3-pro | TipRanks - Google | $3.50 | Hold | −3.0% | Reiterated | 21.09.26on TipRanks Sep 20 23:06 | — | |
| AI PerPlexity Medical - Instruments and SuppliesPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 | Hold | −16.9% | Reiterated | 15.09.26on TipRanks Sep 14 23:05 | — | |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.23 (from $-0.23 to $-0.23). Last quarter: $0.09.
Sales
Next quarter’s sales estimate — $31M (from $31M to $31M). Last quarter: $31M.
Best top-analyst consensus in the sector · Healthcare
About Orasure Technologies
- CEO: Carrie Eglinton Manner
- Employees: 500
- 220 East First Street, Bethlehem, PA, 18015, US
- www.orasure.com
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distr
Data from the stock’s TipRanks forecast page, read 210 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗